Compared with the healthy control group, the levels of SCD40L, SCD25, sTREM-1, and sCD130 in lung cancer patients were significantly different, highlighting their potential as biomarkers for patient stratification and treatment efficacy. The gene discussed is CD40LG; the disease is lung cancer.